fexapotide

Peptideexperimental

Clinical trial activity

7 trials · 2 clinical orgs · 0 marketing orgs

Phase 1

Phase 2

Phase 3

Phase 4

Earliest trial started May 1, 2007 (NCT00759135)

Timeline

2000s

Jan 1, 2007
Earliest Phase 2 Sponsor(trial)
Jan 1, 2009
Earliest Phase 3 Sponsor(trial)

Indications

Studied for

Mechanism of action

UnclearUnclear
Unclear unclear

Chemistry & pharmacology

Loading structure…

SMILES

CC[C@H](C)[C@H](N)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(C)C)C(=O)O)[C@@H](C)CC)[C@@H](C)CC)C(C)C

Mol. weight: 2055.53 g/mol
Chirality: Racemic Mixture
Inorganic: No
Polymer: No
Multi-specific: No

Oral

Parenteral

Topical

Sources

ChEMBLCHEMBL3545061 ↗

Also known as

fexapotide
nx-1207
nx-1207
nx-1207

Clinical trials

NCT ID	Phase	Start date	Sponsor(s)
NCT02003742	Phase 3	Sep 1, 2013	Recordati
NCT01846793	Phase 3	Apr 1, 2013	Nymox Corporation
NCT01620515	Phase 2	Feb 21, 2012	Nymox Corporation
NCT01438775	Phase 3	Sep 1, 2011	Nymox Corporation
NCT00945490	Phase 3	May 1, 2009	Nymox Corporation
NCT00918983	Phase 3	Apr 1, 2009	Nymox Corporation
NCT00759135	Phase 2	May 1, 2007	Nymox Corporation

Showing 7 of 7 trials

Page 1 / 1

Organizations

Research & Development (2)

Organization	Org type	Trials	As lead sponsor	Phases	Earliest year
Nymox Corporation	For profit	6	6	2	2007
Recordati	For profit	1	1	1	2013

2 organizations

Page 1 / 1